Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan vormen van gynaecologische kanker zoals eierstokkanker, baarmoederhalskanker , baarmoederkanker, vulvakanker en endometriumkanker door vooraanstaande artsen en oncologen wereldwijd.
Abstracten aanbevolen door Prof. Dr. Annette Hasenburg:
Prof. Dr. Annette Hasenburg, Director of Obstetrics and Gynecology at the Mainz University Medical Center and a member of the Advisory Board of Practice Update Oncology, recommends the following abstracts to be presented at this year's ESMO Congress, held September 13 through 17, 2024, in Barcelona.
Saturday, September 14, 2024
Poster Presentations
732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): progression-free survival (PFS) by clinical factors in DUO-E. SV Blank, M McCollum, C Anderson, et al
- Up to now, subgroup analyses were performed by MMR status. The additional evaluation of clinical factors will hopefully discriminate which other factors will influence PFS, especially in the diverse subpopulation of pMMR tumors.
Saturday, September 14, 2024
2:45 PM–4:15 PM CEST; Proffered Paper Session
LBA29 Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: results from PRIMA/ENGOT-OV26/GOG-3012. A González-Martín
- It will be shown in a large study population whether improvement of PFS translated into significantly longer OS and how a subsequent PARP inhibitor therapy had an impact on this result.
Saturday, September 14, 2024
4:30 PM–6:15 PM CEST; Presidential Symposium I
709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. D Lorusso
- In patients with high-risk locally advanced cervical cancer, pembrolizumab plus chemoradiotherapy (CCRT) versus placebo plus CCRT showed a significant improvement in OS and had a manageable safety profile. Therefore, CCRT with the addition of pembrolizumab might evolve as a new standard of care.
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "ESMO 2024: aanbevolen abstracten gerelateerd aan vormen van gynaecologische vormen van kanker zoals eierstokkanker, baarmoederhalskanker , baarmoederkanker, vulvakanker en endometriumkanker door vooraanstaande artsen en oncologen wereldwijd"